HYOPZIG
LIVE

Serial Number

97566236

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Aug 26, 2022

Add to watchlist:

No watchlists yet
View on USPTO

HYOPZIG Trademark

Serial Number: 97566236

HYOPZIG is a trademark filed by Bristol-Myers Squibb Company on August 26, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

August 26, 2022

Registration Date

Not Registered

Published for Opposition

July 11, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

SOU TEAS EXTENSION RECEIVED
Feb 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 27, 2025 EXRA
SOU EXTENSION 4 GRANTED
Aug 26, 2025 EX4G
SOU EXTENSION 4 FILED
Aug 26, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 26, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 3 GRANTED
Mar 4, 2025 EX3G
SOU EXTENSION 3 FILED
Mar 4, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 20, 2024 EXRA
SOU EXTENSION 2 GRANTED
Aug 20, 2024 EX2G
SOU EXTENSION 2 FILED
Aug 20, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 9, 2024 EXRA
SOU EXTENSION 1 GRANTED
Feb 7, 2024 EX1G
SOU EXTENSION 1 FILED
Feb 7, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 7, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 5, 2023 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 11, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 11, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 21, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 2, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 2, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 9, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 9, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 9, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 8, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2022 NWOS
NEW APPLICATION ENTERED
Aug 30, 2022 NWAP